ADXS News and Press, Advaxis From 05/23/23

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update. “Our immediate priority is to complete enr...

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it will present a poster featuring data from the RINGSIDE study of AL102 at the 2023 American Society of Clinical Onco...

2023-04-14 10:25:31 ET Summary SpringWorks Therapeutics, Inc. has had a spate of troubles with data recently. However, its lead asset has a near-term PDUFA, and approval looks likely. SpringWorks Therapeutics has a decent cash runway. I covered Pfizer (PFE) spinoff ...

Ayala Pharmaceuticals ( OTCQX:ADXS ) announces that the Independent Data Monitoring Committee (IDMC) for its Phase 2/3 RINGSIDE study evaluating AL102 in desmoid tumors conducted a prespecified periodic review of data and recommended that the study continue without modifications. The ...

Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Updated data on AL102 Phase 2 segment of RINGSIDE are planned for presentation at a medical meeting in 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceutic...

Advaxis press release ( OTCQX:ADXS ): FY GAAP EPS of -$8.46. Revenue of $0.25M, compared with $3.2M for the fiscal year 2021. Cash position On October 31, 2022, the consolidated cash and cash equivalents position was $25.2M. For further details see: Advaxis GAAP EPS of -...

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company,...

REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytoge...

Ayala Pharmaceuticals' ( NASDAQ: AYLA ) last day of trading is at market close Wednesday as the company's merger with Advaxis ( OTCQX:ADXS ) takes place. Advaxis ( OTCQX:ADXS ) is up 26% . Ayala ( AYLA ) stockholders will own ~62.5% of the combined company, while t...

Ayala Pharmaceuticals ( NASDAQ: AYLA ) and Advaxis ( OTCQX:ADXS ) are merging in an all stock transaction to focus on the development of cancer therapies. Under the agreement, each outstanding common share of Ayala will be converted into the right to receive com...